Compositions and Methods for Treatment of Cancer
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
1 . A human memory T cell comprising a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the human memory T cell is of a human having cancer.
2 . The human memory T cell of claim 1 , wherein the CD19 antigen binding domain is a Fab or scFv.
3 . The human memory T cell of claim 2 , wherein the CD19 antigen binding domain is a scFv.
4 . The human memory T cell of claim 1 , wherein the transmembrane domain comprises CD8 transmembrane domain.
5 . The human memory T cell of claim 1 , wherein the co-stimulatory signaling region is CD27 or 4-1BB.
6 . The human memory T cell of claim 1 , wherein the CAR further comprises a hinge region.
7 . The human memory T cell of claim 6 , wherein the hinge region comprises a CD8α hinge region.
8 . A human memory T cell comprising a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the human memory T cell is of a human having cancer.
9 . The human memory T cell of claim 8 , wherein the CD19 antigen binding domain is a Fab or scFv.
10 . The human memory T cell of claim 9 , wherein the CD19 antigen binding domain is a scFv.
11 . The human memory T cell of claim 8 , wherein the transmembrane domain comprises CD8 transmembrane domain.
12 . The human memory T cell of claim 8 , wherein the co-stimulatory signaling region is CD27 or 4-1BB.
13 . The human memory T cell of claim 8 , wherein the CAR further comprises a hinge region.
14 . The human memory T cell of claim 13 , wherein the hinge region comprises a CD8α hinge region.
15 . A persisting population of human T cells comprising a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the persisting population of T cells are of a human having cancer.
16 . The persisting population of human T cells of claim 15 , wherein the CD19 antigen binding domain is a Fab or scFv.
17 . The persisting population of human T cells of claim 16 , wherein the CD19 antigen binding domain is a scFv.
18 . The persisting population of human T cells of claim 15 , wherein the transmembrane domain comprises CD8 transmembrane domain.
19 . The persisting population of human T cells of claim 15 , wherein the co-stimulatory signaling region is CD27 or 4-1BB.
20 . The persisting population of human T cells of claim 15 , wherein the CAR further comprises a hinge region.
21 . The persisting population of human T cells of claim 20 , wherein the hinge region comprises a CD8α hinge region.
22 . A persisting population of human T cells comprising a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the persisting population of T cells are of a human having cancer.
23 . The persisting population of human T cells of claim 22 , wherein the CD19 antigen binding domain is a Fab or scFv.
24 . The persisting population of human T cells of claim 23 , wherein the CD19 antigen binding domain is a scFv.
25 . The persisting population of human T cells of claim 22 , wherein the transmembrane domain comprises CD8 transmembrane domain.
26 . The persisting population of human T cells of claim 22 , wherein the co-stimulatory signaling region is CD27 or 4-1BB.
27 . The persisting population of human T cells of claim 22 , wherein the CAR further comprises a hinge region.
28 . The persisting population of human T cells of claim 27 , wherein the hinge region comprises a CD8α hinge region.